These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 1027470)

  • 1. [Effects of fractional or massive doses of exogenous ESF in uremic patients].
    Lamperi S; Fiorio P
    Boll Soc Ital Biol Sper; 1976 Dec; 52(23):1978-84. PubMed ID: 1027470
    [No Abstract]   [Full Text] [Related]  

  • 2. [The comparative characteristics of parlodel, zinc sulfate and recombinant erythropoietin in treating uremic hypogonadism in patients on chronic hemodialysis].
    Kukhtevich AV; Ermolenko VM; Dedov II; Gitel' EP; Buniatian AF; Smirnova GA
    Ter Arkh; 1992; 64(11):66-70. PubMed ID: 1293848
    [No Abstract]   [Full Text] [Related]  

  • 3. [Recombinant human erythropoietin in uremic patients in substitute treatment].
    Canaud B; Mion C
    Rev Prat; 1992 Feb; 42(4):432-40. PubMed ID: 1604162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.
    Buemi M; Allegra A; Laganà A; Aloisi C; Privitera M; Morabito N; Frisina N
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):195-7. PubMed ID: 7761669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum erythropoietin (ESF) titers in anemia of chronic renal failure.
    de Klerk G; Wilmink JM; Rosengarten PC; Vet RJ; Goudsmit R
    J Lab Clin Med; 1982 Nov; 100(5):720-34. PubMed ID: 7130829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of iron treatment in the optimization of the use of erythropoietin (EPO) in hemodialyzed patients].
    Cigarrán S; Barril G
    Nefrologia; 2001; 21(5):510-1. PubMed ID: 11795024
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
    Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
    Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
    Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
    Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance and use of iron supplementation in uremia.
    Makoff R
    Nephrol News Issues; 1992 Jun; 6(6):14-6, 19. PubMed ID: 1608475
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous iron administration during the maintenance period in erythropoietin-treated hemodialysis patients: a simple and effective method.
    Nurnuansuwan S; Leelahavanichkul A; Pansin P; Eiam-Ong S
    J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S184-8. PubMed ID: 16623026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of iron status monitoring during erythropoietin treatment in uremic predialysis patients.
    Rutkowski B; Debska-Slizień A; Biedunkiewicz B; Bułło B
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():17-21. PubMed ID: 8192528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron status of dialysis patients under rhuEPO therapy.
    Hörl WH; Dreyling K; Steinhauer HB; Engelhardt R; Schollmeyer P
    Contrib Nephrol; 1990; 87():78-86. PubMed ID: 2093543
    [No Abstract]   [Full Text] [Related]  

  • 13. [Results of treating uremia anemia with human recombinant erythropoietin].
    Litwin M; Grenda R; Jelonek A
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):132-4. PubMed ID: 8090664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations of iron management in chronic kidney patients].
    Canaud B
    Nephrol Ther; 2006 Nov; 2 Suppl 5():S356-62. PubMed ID: 17373284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 16. Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients.
    Sezer S; Tutal E; Bilgic A; Ozdemir FN; Haberal M
    Transplant Proc; 2007; 39(1):40-4. PubMed ID: 17275471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
    Fernández-Gallego J; Martín MA; Alonso A; Toledo R
    Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis.
    Wideröe TE; Sanengen T; Halvorsen S
    Kidney Int Suppl; 1983 Dec; 16():S208-17. PubMed ID: 6588251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.